Home / Tag Archives: Biomedical Advanced Research and Development Authority

Tag Archives: Biomedical Advanced Research and Development Authority

Emergent BioSolutions to Deliver Anthrax Vaccines to National Stockpile Under $100M BARDA Contract

Emergent BioSolutions (NYSE: EBS) has received a potential two-year, $100 million contract from the Biomedical Advanced Research and Development Authority to deliver BioThrax anthrax vaccines to the Strategic National Stockpile. The award came three months after the Centers for Disease Control and Prevention awarded Emergent a potential $911 million follow-on contract to supply …

Read More »

SRI International Lands 2 BARDA Nonclinical Research Service Contracts Worth $90M

SRI International has received a pair of contracts worth a combined $90 million to help  the Biomedical Advanced Research and Development Authority assess compounds that have potential to treat people exposed to chemical, biological, radiological or nuclear weapons. The company said Wednesday that both contracts have a base period of five years and cover …

Read More »

Emergent BioSolutions Gets $199M HHS Funds to Mature Anthrax Vaccine Candidate

The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the development of an anthrax vaccine in preparation for a Food and Drug Administration license. The HHS office of the assistant secretary for preparedness and response’s Biomedical Advanced Research and Development …

Read More »

Sanofi Pasteur Receives Potential $173.4M HHS Contract to Develop Inactivated Zika Vaccine

The Department of Health and Human Services has awarded a potential $173.6 million contract to Sanofi Pasteur for work to develop inactivated vaccine candidate that could help prevent Zika virus infection and associated birth defects. HHS said Monday the contract has a $43.2 million base value that covers process development, scale up, clinical trial material production …

Read More »

BARDA to Support Altimmune Anthrax Vaccine Clinical Trials Under $120M Contract

Altimmune has received a potential five-year, $120.2 million contract from the Biomedical Advanced Research and Development Authority to conduct clinical trials on an experimental vaccine against anthrax. The Gaithersburg, Maryland-based immunotherapeutic company will test its NasoShield intranasal anthrax vaccine through Phase 1 clinical studies under the contract’s base term worth approximately $14.3 …

Read More »

Emergent BioSolutions Lands BARDA Task Order for Zika Vaccine Development

The Biomedical Advanced Research and Development Authority has awarded Emergent BioSolutions (NYSE: EBS) a potential $21.9 million task order to develop and produce a vaccine against Zika virus for use in the first phase of a clinical trial. The company said Monday the order has a base period of 30 months …

Read More »

CDC Awards Emergent BioSolutions New Anthrax Vaccine Development Funds

The Department of Health and Human Services has tapped Emergent BioSolutions to further develop a new anthrax vaccine under a 30-month, $31 million contract with funding and technical support from the Biomedical Advanced Research and Development Authority. HHS said Monday the new vaccine, called NuThrax, will work to improve on the existing licensed vaccine as …

Read More »